Plasma levels of total cholesterol, high-density lipoprotein-cholesterol, low-density lipoprotein-cholesterol, triglyceride, Apo A-1, and Apo B in patients with Stroke in Ogbomoso, Southwestern Nigeria

ABSTRACT

Hyperlipidemia is a strong factor in the development of stroke, but this may differ from one region to anotherdue to geographic, ethnic, and sociocultural practices. This is designed to determine plasma levels of totalcholesterol, high-density lipoprotein (HDL)-cholesterol, low-density lipoprotein (LDL)-cholesterol, triglyceride,Apoprotein A-1, and Apoprotein B in Nigerian patients with stroke. 50 newly diagnosed stroke patients wereconsecutively recruited into the study. 50 apparently healthy, age- and sex-matched volunteers were recruited fromOgbomoso community as controls. The data obtained were analyzed using the Statistical Package for the SocialSciences (SPSS) version 20. Higher and lower significant levels (P < 0.001), respectively, were observed in theplasma total cholesterol (4.5 ± 1.41 vs. 3.90 ± 0.91 mmol/l), LDL-cholesterol (3.32 ± 1.41 vs. 2.19 ± 0.82 mmol/l),HDL-cholesterol (0.76 ± 0.32 vs. 1.27 ± 0.38 mmol/l), and Apo A1 (0.87 ± 0.73 vs. 4.56 ± 2.40) in stroke patientswhen compared with controls. There was a lower significant difference in plasma level of Apo A1 in patients withischemic stroke (0.734 ± 0.64 vs. 1.31 ± 0.84) when compared with hemorrhagic stroke (P < 0.005). The meanplasma level of Apo B (1.70 ± 1.05 vs. 1.09 ± 0.40) in ischemic stroke was higher than patients with hemorrhagicstroke, though difference was not statistically significant (P ≥ 0.005). We concluded that apoproteins remain thesignificant biochemical markers that may be deranged in patients with stroke. There are associations between ApoA1 and Apo B. It is encouraged that plasma apoproteins estimation should be added to routine investigations doneon stroke patients in this environment.